Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ALT

Altimmune Inc

Feb 09 • 04:00PM ET

4.69

-0.18 -3.70 %

Healthcare • Biotechnology • USA • NASD

Peers: NVAX INO VXRT XFOR ADMA AGEN BCRX ANIX DTIL AVIR

| Held by: XBI VTI IWM VXF IBB IWO FESM VTWO IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-1.07	Insider Own	0.85%	Shs Outstand	104.34M	Perf Week	-15.50%
Market Cap	587.34M	Forward P/E	-	EPS next Y	-1.21	Insider Trans	2.95%	Shs Float	103.46M	Perf Month	14.95%
Enterprise Value	392.42M	PEG	-	EPS next Q	-0.23	Inst Own	43.10%	Short Float	25.52%	Perf Quarter	19.04%
Income	-83.92M	P/S	29366.91	EPS this Y	27.16%	Inst Trans	5.85%	Short Ratio	5.31	Perf Half Y	35.94%
Sales	0.02M	P/B	2.42	EPS next Y	-23.82%	ROA	-45.82%	Short Interest	26.41M	Perf YTD	29.92%
Book/sh	1.94	P/C	2.79	EPS next 5Y	8.87%	ROE	-52.61%	52W High	7.73 -39.33%	Perf Year	-32.13%
Cash/sh	1.68	P/FCF	-	EPS past 3/5Y	17.12% 3.48%	ROIC	-41.70%	52W Low	2.90 61.72%	Perf 3Y	-68.82%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-83.45% -67.83%	Gross Margin	-495.00%	Volatility	7.41% 9.43%	Perf 5Y	-73.20%
Dividend TTM	-	EV/Sales	19620.91	EPS Y/Y TTM	31.25%	Oper. Margin	-452310.00%	ATR (14)	0.45	Perf 10Y	-91.83%
Dividend Ex-Date	-	Quick Ratio	17.18	Sales Y/Y TTM	-61.54%	Profit Margin	-419575.00%	RSI (14)	46.91	Recom	1.70
Dividend Gr. 3/5Y	- -	Current Ratio	17.18	EPS Q/Q	33.85%	SMA20	-5.00%	Beta	0.10	Target Price	19.75
Payout	-	Debt/Eq	0.09	Sales Q/Q	0.00%	SMA50	-0.96%	Rel Volume	0.74	Prev Close	4.87
Employees	59	LT Debt/Eq	0.08	Earnings	Nov 06 BMO	SMA200	2.76%	Avg Volume	4.97M	Price	4.69
IPO	Oct 06, 2005	Option/Short	Yes / Yes	EPS/Sales Surpr.	22.82% 257.14%	Trades		Volume	3,706,123	Change	-3.70%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Initiated	Barclays	Overweight	$20
Jul-10-25	Resumed	Goldman	Sell	$1
Feb-28-25	Initiated	William Blair	Mkt Perform
Jan-08-25	Initiated	Stifel	Buy	$18
Nov-12-24	Initiated	UBS	Buy	$26
Apr-29-24	Downgrade	Guggenheim	Buy → Neutral
Jan-24-24	Initiated	Goldman	Neutral	$13
Mar-22-23	Downgrade	Goldman	Buy → Neutral	$20 → $6
Dec-01-22	Initiated	Goldman	Buy	$20
Dec-29-21	Resumed	Jefferies	Buy	$30
Jun-02-21	Initiated	H.C. Wainwright	Buy	$35
Feb-11-21	Initiated	Guggenheim	Buy	$36
Dec-14-20	Initiated	Jefferies	Buy	$25
Nov-12-20	Reiterated	B. Riley Securities	Buy	$31 → $28
Sep-25-20	Initiated	B. Riley FBR	Buy	$31
Aug-14-20	Initiated	Evercore ISI	Outperform
Jul-31-20	Initiated	Piper Sandler	Overweight	$80
Jul-28-20	Initiated	JMP Securities	Mkt Outperform	$50
Feb-24-20	Resumed	ROTH Capital	Buy	$13
Jul-19-19	Initiated	ROTH Capital	Buy	$8.30

Show Previous Ratings

Feb-02-26 09:55AM	Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development (Insider Monkey)
Jan-29-26 05:54PM	Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock (GlobeNewswire) +9.80%
01:31PM	Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration (PR Newswire)
Jan-28-26 04:13PM	Altimmune (ALT) Shares Slide On $75 Million Stock Offering (Benzinga) -17.15%
Jan-27-26 09:25PM	Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock (GlobeNewswire) +9.19%
02:06PM	Loading…
Jan-23-26 02:06PM	Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly (24/7 Wall St.)
09:40AM	Unusually active option classes on open January 22nd (TipRanks)
Jan-06-26 11:53AM	ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH (Zacks)
Jan-05-26 07:30AM	Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH (GlobeNewswire) +16.52%
Dec-29-25 10:15AM	3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround (Zacks)
Dec-19-25 06:30AM	Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial (GlobeNewswire) -22.77%
Dec-11-25 09:55AM	Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect? (Zacks)
Dec-01-25 07:30AM	Altimmune Announces CEO Transition and Succession Plan (GlobeNewswire) -6.27%
Nov-26-25 07:30AM	Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-25-25 09:55AM	Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know (Zacks)
08:51AM	Loading…
Nov-11-25 08:51AM	Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting 2025 (GlobeNewswire)
Nov-08-25 06:05AM	Altimmune price target lowered to $14 from $15 at Citizens JMP (TipRanks)
Nov-07-25 08:05AM	Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting 2025 (GlobeNewswire)
Nov-06-25 07:00AM	Altimmune Announces Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire) +5.07%
Nov-05-25 07:30AM	Altimmune to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Nov-03-25 07:30AM	Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder (GlobeNewswire)
Oct-31-25 11:18AM	3 Explosive Stocks With High Short Interest (24/7 Wall St.)
Oct-30-25 07:30AM	Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 (GlobeNewswire)
Oct-20-25 07:30AM	Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting 2025 (GlobeNewswire)
Oct-01-25 08:45AM	Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
Sep-30-25 10:52AM	Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights ALT (Business Wire)
Sep-29-25 07:30AM	Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide (GlobeNewswire) -5.25%
Sep-23-25 07:30AM	Altimmune to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Sep-15-25 07:30AM	Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer (GlobeNewswire)
Sep-09-25 09:00AM	Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT (PR Newswire)
08:45AM	Loading…
Sep-02-25 08:45AM	Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
Aug-26-25 08:45AM	Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
07:30AM	Altimmune to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-19-25 07:30AM	Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) (GlobeNewswire)
Aug-14-25 04:34PM	Investors in Altimmune, Inc. (ALT): Protect Your Rights - Contact Levi & Korsinsky Before October 6, 2025 (Newsfile)
Aug-13-25 04:24PM	Altimmune, Inc. (ALT) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before October 6, 2025 (Newsfile)
03:07AM	Altimmune Inc (ALT) Q2 2025 Earnings Call Highlights: Strong Cash Position and Promising Drug ... (GuruFocus.com)
Aug-12-25 07:00AM	Altimmune Announces Second Quarter 2025 Financial Results and Business Update (GlobeNewswire) +7.10%
Aug-11-25 07:30AM	Altimmune Board of Directors Appoints Jerry Durso as Chairman (GlobeNewswire)
Aug-05-25 07:30AM	Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 (GlobeNewswire)
Jul-25-25 08:46AM	Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
Jul-09-25 07:30AM	Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) (GlobeNewswire)
01:19AM	Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial (Insider Monkey)
Jun-26-25 07:00AM	Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH (GlobeNewswire) -53.18%
Jun-25-25 07:12PM	Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 (GlobeNewswire) +7.23%
Jun-18-25 09:53AM	Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. (Motley Fool)
Jun-13-25 07:30AM	Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions (GlobeNewswire)
May-21-25 11:17AM	Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential (Insider Monkey)
May-19-25 07:30AM	Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) (GlobeNewswire)
May-14-25 09:18AM	Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension (TipRanks)
07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-13-25 07:00AM	Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital (GlobeNewswire)
07:00AM	Altimmune Announces First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
May-12-25 01:01PM	Will Healthy Y/Y Revenue Growth Boost Keysight's Q2 Earnings? (Zacks) +7.51%
06:33AM	Doximity Q4 Earnings Likely to Reflect Strong Product Momentum (Zacks)
May-09-25 09:55AM	How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% (Zacks)
May-08-25 07:30AM	Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress (GlobeNewswire) +8.21%
May-06-25 07:30AM	Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 (GlobeNewswire) -7.37%
May-01-25 07:30AM	Altimmune to Present at Upcoming EASL International Liver Congress 2025 (GlobeNewswire)
Apr-30-25 07:30AM	Altimmune to Participate in the Citizens Life Sciences Conference (GlobeNewswire)
04:51AM	Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? (Motley Fool)
04:51AM	Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? (Motley Fool)
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Mar-22-25 06:44AM	Buying These Dirt-Cheap Stocks Could Be a Brilliant Move (Motley Fool)
Mar-19-25 04:33PM	Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts (InsiderMonkey)
Mar-06-25 07:30AM	Altimmune to Host Virtual R&D Day on March 13, 2025 (GlobeNewswire)
Mar-03-25 07:30AM	Altimmune to Participate in the Leerink Global Healthcare Conference (GlobeNewswire) -9.92%
Feb-27-25 07:00AM	Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire) +8.08%
Feb-25-25 07:30AM	Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors (GlobeNewswire)
Feb-20-25 07:30AM	Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 (GlobeNewswire)
Jan-29-25 07:30AM	Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-28-24 03:39PM	Jim Cramer on Altimmune, Inc. (ALT): and#8216;Healthcare Is So Out Of Fashion' (Insider Monkey)
Dec-19-24 07:30AM	Altimmune Added to Nasdaq Biotechnology Index (GlobeNewswire)
Dec-17-24 08:13PM	Lightning Round: Ford's warranty problems will come back to haunt it, says Jim Cramer (CNBC TV) -6.67% -5.95%
Dec-03-24 06:22PM	Altimmune CEO on what's next for its experimental obesity drug (CNBC TV) +12.06%
Dec-02-24 07:30AM	Altimmune to Present at the Cachexia Regulatory and Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders (GlobeNewswire)
07:30AM	Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders (GlobeNewswire)
Nov-26-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-15-24 11:00AM	Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting 2024 (GlobeNewswire) -9.99%
Nov-12-24 07:00AM	Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +29.12%
Nov-11-24 07:30AM	Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire)
07:30AM	Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-24 07:30AM	Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity (GlobeNewswire)
Nov-06-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 07:30AM	Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 (GlobeNewswire)
Oct-15-24 08:00AM	Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting 2024 (GlobeNewswire) +9.49%
Oct-01-24 07:30AM	Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference (GlobeNewswire)
Sep-30-24 07:30AM	Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) (GlobeNewswire) -5.10%
Sep-10-24 01:09PM	CORRECTION Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire) +9.09%
07:45AM	Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Sep-03-24 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Aug-08-24 07:00AM	Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +15.09%
Aug-07-24 07:00AM	CytoSorbents to Report Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -7.02%
Aug-01-24 07:30AM	Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (GlobeNewswire)
Jul-25-24 07:30AM	Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology (GlobeNewswire) +6.70%
Jul-09-24 06:42AM	7 Bullish Stock Picks With the Potential to Turn $5K Into $50K (InvestorPlace)
Jul-06-24 08:00AM	The 7 Best Under $10 Stocks to Buy in July 2024 (InvestorPlace)
Jul-02-24 07:30AM	Altimmune to Participate at Leerink Partners Therapeutics Forum (GlobeNewswire) -6.39%
Jun-28-24 10:09AM	The 3 Smartest Biotech Stocks to Buy With $5K Right Now (InvestorPlace)
01:55AM	Altimmune, Inc. (ALT): Why Are Hedge Funds Shorting This Biopharmaceutical Stock? (Insider Monkey)

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Roberts M Scot	Chief Scientific Officer	Feb 02 '26	Option Exercise	0.00	7,775	0	115,153	Feb 03 04:15 PM
Roberts M Scot	Chief Scientific Officer	Jan 30 '26	Option Exercise	0.00	9,275	0	104,670	Feb 03 04:15 PM
Garg Vipin K	Director	Jan 30 '26	Option Exercise	0.00	26,775	0	429,225	Feb 02 04:15 PM
Jordt Raymond M	Chief Business Officer	Jan 27 '26	Option Exercise	0.00	15,850	0	69,765	Jan 29 04:15 PM
Garg Vipin K	Director	Jan 27 '26	Option Exercise	0.00	41,200	0	420,348	Jan 29 04:10 PM
Roberts M Scot	Chief Scientific Officer	Jan 27 '26	Option Exercise	0.00	15,850	0	100,143	Jan 29 04:05 PM
Jordt Raymond M	Chief Business Officer	Jan 25 '26	Option Exercise	0.00	14,600	0	57,770	Jan 27 07:10 AM
Garg Vipin K	Director	Jan 25 '26	Option Exercise	0.00	42,050	0	397,132	Jan 27 07:05 AM
Roberts M Scot	Chief Scientific Officer	Jan 25 '26	Option Exercise	0.00	14,600	0	88,666	Jan 27 07:00 AM
Pisano Wayne	Director	Jan 08 '26	Buy	4.08	5,000	20,410	13,498	Jan 09 04:10 PM
Jordt Raymond M	Chief Business Officer	Jan 01 '26	Option Exercise	0.00	9,375	0	45,645	Jan 05 04:10 PM
Jorkasky Diane	Director	Dec 29 '25	Buy	3.80	527	2,003	527	Dec 29 04:10 PM
GILL JOHN	Director	Dec 23 '25	Buy	4.10	12,500	51,250	12,500	Dec 23 04:10 PM
Durso Jerome Benedict	Director	Dec 22 '25	Buy	4.13	12,500	51,569	12,500	Dec 22 04:10 PM
WEAVER GREGORY L	Chief Financial Officer	Nov 11 '25	Option Exercise	0.00	18,750	0	28,750	Nov 12 04:07 PM
Sohn Catherine A.	Director	Mar 17 '25	Buy	5.78	1,000	5,784	1,000	Mar 18 04:15 PM
WEAVER GREGORY L	Chief Financial Officer	Mar 13 '25	Buy	5.20	10,000	51,996	10,000	Mar 14 07:27 AM

Open in Screener

ATOS

Atossa Therapeutics Inc

Feb 09 • 04:00PM ET

4.99

-0.35 -6.55 %

Healthcare • Biotechnology • USA • NASD

ATOS Atossa Therapeutics Inc daily Stock Chart

Peers: MRNA SRPT BNTX CYTK AXSM NVAX KPTI ADAP RGLS

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-3.52	Insider Own	0.31%	Shs Outstand	8.61M	Perf Week	-10.73%
Market Cap	42.98M	Forward P/E	-	EPS next Y	-4.33	Insider Trans	0.00%	Shs Float	8.58M	Perf Month	-49.06%
Enterprise Value	-8.97M	PEG	-	EPS next Q	-1.14	Inst Own	19.38%	Short Float	2.81%	Perf Quarter	-59.16%
Income	-30.18M	P/S	-	EPS this Y	-30.44%	Inst Trans	-	Short Ratio	2.05	Perf Half Y	-57.73%
Sales	0.00M	P/B	0.86	EPS next Y	-10.56%	ROA	-43.90%	Short Interest	0.24M	Perf YTD	-43.62%
Book/sh	5.78	P/C	0.83	EPS next 5Y	-16.39%	ROE	-48.89%	52W High	19.35 -74.21%	Perf Year	-58.67%
Cash/sh	6.03	P/FCF	-	EPS past 3/5Y	-4.77% 36.92%	ROIC	-60.62%	52W Low	4.91 1.73%	Perf 3Y	-59.92%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.66% 11.17%	Perf 5Y	-88.12%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-9.45%	Oper. Margin	-	ATR (14)	0.87	Perf 10Y	-99.35%
Dividend Ex-Date	-	Quick Ratio	6.77	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	22.02	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.77	EPS Q/Q	-17.07%	SMA20	-38.84%	Beta	1.38	Target Price	75.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-48.70%	Rel Volume	2.76	Prev Close	5.34
Employees	15	LT Debt/Eq	0.00	Earnings	Nov 12 BMO	SMA200	-58.57%	Avg Volume	117.86K	Price	4.99
IPO	Nov 08, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	-7.69% -	Trades		Volume	325,014	Change	-6.55%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-26-18	Initiated	Maxim Group	Buy	$2

Feb-05-26 08:30AM	Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program (PR Newswire)
Jan-21-26 09:05AM	Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 (PR Newswire)
Jan-16-26 04:40PM	Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy (PR Newswire) +6.02%
Dec-17-25 08:15AM	Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category (PR Newswire)
Dec-15-25 08:00AM	Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium (PR Newswire) -13.37%
08:00AM	Loading…
Dec-11-25 08:00AM	Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy (PR Newswire) +6.45%
Dec-09-25 08:00AM	Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen (PR Newswire)
Dec-04-25 08:00AM	Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum (PR Newswire)
Dec-02-25 08:00AM	Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma (PR Newswire) -5.65%
Nov-17-25 09:07AM	Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation (PR Newswire)
Nov-12-25 08:15AM	Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (PR Newswire)
Nov-06-25 08:00AM	Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium (PR Newswire)
Oct-22-25 06:31AM	New Strong Sell Stocks for Oct. 22 (Zacks)
Oct-21-25 08:00AM	Atossa Therapeutics Highlights Progress in RECAST DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents (PR Newswire)
Oct-15-25 08:00AM	Atossa Therapeutics to Present at the Maxim Growth Summit 2025 (PR Newswire)
08:00AM	Loading…
Oct-14-25 08:00AM	Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness (PR Newswire)
06:07AM	New Strong Sell Stocks for Oct. 14th (Zacks)
Oct-13-25 08:00AM	Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals (PR Newswire)
Oct-06-25 08:00AM	Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities (PR Newswire)
Oct-01-25 08:30AM	Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones (PR Newswire) +5.67%
Sep-17-25 08:00AM	Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services (GlobeNewswire)
Sep-08-25 08:30AM	Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction (PR Newswire)
Aug-28-25 08:30AM	Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference (PR Newswire)
Aug-20-25 08:30AM	Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer (PR Newswire)
Aug-12-25 08:30AM	Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update (PR Newswire)
Jul-29-25 07:45AM	Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer (PR Newswire) +13.14%
Jul-02-25 10:03PM	Ascendiant Lifts Atossa Therapeutics, Inc. (ATOS) Target Citing Strong Liquidity (Insider Monkey)
Jun-02-25 08:45AM	Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference (PR Newswire) +11.54%
May-20-25 09:00AM	Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 (ACCESSWIRE)
May-15-25 09:40AM	Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? (Zacks)
08:15AM	Loading…
May-14-25 08:15AM	Atossa Therapeutics Announces Full Results from I-SPY?2 Endocrine-Optimization Sub-Study Evaluating Low-Dose (Z)-Endoxifen (PR Newswire) +15.73%
May-13-25 08:00AM	Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update (PR Newswire) +6.34%
Apr-30-25 08:45AM	Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio (GlobeNewswire) +12.87%
Apr-29-25 08:45AM	Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025 (GlobeNewswire) +7.09%
Apr-22-25 08:45AM	Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio (GlobeNewswire)
Apr-10-25 08:00AM	Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer (PR Newswire)
Mar-28-25 12:00PM	All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy (Zacks)
Mar-25-25 10:05AM	Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript (SeekingAlpha)
08:00AM	Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-20-25 09:13AM	Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-11-25 08:15AM	Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications (GlobeNewswire)
Feb-05-25 08:00AM	Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care (GlobeNewswire)
Jan-30-25 08:17AM	Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591 (GlobeNewswire)
Jan-23-25 08:15AM	Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 (GlobeNewswire)
Jan-06-25 09:00AM	Atossa Therapeutics Applauds U.S. Surgeon General's Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer (GlobeNewswire)
Dec-20-24 09:40AM	Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-13-24 08:20AM	Atossa Therapeutics to present poster on Z-endoxifen at SABCS (TipRanks)
Dec-12-24 08:15AM	Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -5.74%
Dec-11-24 08:15AM	Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density (GlobeNewswire)
Dec-10-24 09:05AM	Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-09-24 08:15AM	Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research (GlobeNewswire)
Nov-21-24 08:30AM	Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research (GlobeNewswire)
Nov-20-24 08:30AM	Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -6.25%
Nov-12-24 08:30AM	Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -7.41%
Nov-05-24 08:30AM	Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development (GlobeNewswire)
Nov-04-24 06:30AM	Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results: (GlobeNewswire)
Oct-31-24 08:15AM	Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer (GlobeNewswire)
Oct-28-24 09:40AM	Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? (Zacks)
Oct-21-24 08:30AM	Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer (GlobeNewswire)
Oct-15-24 07:32AM	Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women (PR Newswire)
Oct-14-24 05:08PM	Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-01-24 08:30AM	Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum (GlobeNewswire)
Sep-19-24 09:40AM	Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-10-24 08:30AM	Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer (GlobeNewswire) +7.35%
Sep-03-24 09:40AM	Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year? (Zacks)
08:30AM	Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-30-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice (Zacks)
Aug-28-24 08:30AM	Atossa Therapeutics Granted Additional Patent Protection for Endoxifen (GlobeNewswire)
Aug-21-24 11:30AM	Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer (GlobeNewswire)
Aug-20-24 08:30AM	Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations (GlobeNewswire)
Aug-12-24 08:30AM	Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +5.98%
Jul-22-24 08:30AM	Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer (GlobeNewswire) +10.45%
Jul-11-24 09:40AM	Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? (Zacks) +6.67%
07:00AM	3 Dirt-Cheap Drug Developers With Blockbuster Potential (InvestorPlace)
Jul-03-24 09:45AM	3 Penny Stock Moonshots with 300%+ Upside Potential by 2025 (InvestorPlace)
Jul-02-24 04:15PM	Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer (GlobeNewswire)
Jun-28-24 08:30AM	Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO ) in Women with ER+/HER2- Breast Cancer (GlobeNewswire)
Jun-17-24 08:30AM	Atossa Set to Join Russell 3000 Index Effective June 28, 2024 (GlobeNewswire)
Jun-11-24 10:50AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
Jun-07-24 07:30AM	Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar (InvestorPlace)
Jun-06-24 09:40AM	Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-05-24 08:30AM	Atossa to Present at the Sidoti Small-Cap Investor Conference (GlobeNewswire)
May-28-24 08:30AM	Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model (GlobeNewswire)
May-20-24 12:00PM	Atossa Genetics Inc. (ATOS) is a Great Momentum Stock: Should You Buy? (Zacks)
06:00AM	3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off (InvestorPlace)
May-17-24 06:15AM	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 (InvestorPlace)
May-15-24 08:30AM	Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial (GlobeNewswire)
May-13-24 02:52PM	ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:50AM	Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-24 08:30AM	Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines (GlobeNewswire)
Apr-30-24 10:30AM	As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response (PR Newswire)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
08:30AM	Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen (GlobeNewswire)
Apr-15-24 08:30AM	Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO ) in Women with ER+/HER2- Breast Cancer (GlobeNewswire)
Apr-11-24 10:10AM	Atossa (ATOS) Reports Positive Results From EVANGELINE Study (Zacks)
08:30AM	Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference (GlobeNewswire)
Apr-09-24 11:59AM	Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen (GlobeNewswire) +5.14%
Apr-01-24 10:53PM	ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +11.11% -8.00%
04:00PM	Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-19-24 08:30AM	Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved 'Expanded Access' Program for a U.S. Breast Cancer Patient (GlobeNewswire) +20.16%

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
QUAY STEVEN C	President & CEO	May 21 '25	Buy	0.88	11,239	9,887	13,898	May 22 06:27 PM
Remmel H. Lawrence	Director	Mar 26 '25	Buy	0.70	10,000	7,000	10,257	Mar 28 04:00 PM

ALT

Altimmune Inc

ATOS

Atossa Therapeutics Inc

Upgrade your FINVIZ experience